| Issue Date | Title | Author(s) |
| 2024 | Antiparkinsonian activity of selective MAO-B inhibitors of different chemical structures | Fedorov, V. N.; Korsakov, M. K.; Shetnev, A. A.; Petukhov, S. S.; Volkhin, N. N. |
| 2023 | Development of quantification methods of a new selective carbonic anhydrase II inhibitor in plasma and blood and study of the pharmacokinetics of its ophthalmic suspension in rats | Khokhlov, A. L.; Yaichkov, I. I.; Korsakov, M. K.; Shetnev, A. A.; Volkhin, N. N. |
| 2024 | Identification and synthesis of metabolites of 4-(5-methyl-1,3,4-oxadiazole-2-yl)-benzenesulfonamide | Khokhlov, A. L.; Yaichkov, I. I.; Shetnev, A. A.; Panova, V. A.; Efimova, Yu. A. |
| 2024 | Identification and synthesis of metabolites of the new 4.5-dihydroisoxazol-5-carboxamide derivate | Khokhlov, A. L.; Yaichkov, I. I.; Alexeev, M. A.; Korsakov, M. K.; Shetnev, A. A. |
| 2024 | Identification and synthesis of metabolites of the new antiglaucoma drug | Khokhlov, A. L.; Yaichkov, I. I.; Korsakov, M. K.; Shetnev, A. A.; Ivanovskiy, S. A. |
| 2023 | Screening of anti-inflammatory activity of 4.5- dihydroisoxazol-5-carboxamide (PAR-2 inhibitors) based on formaldehyde oedema model among white lab rats | Korsakov, M. K.; Fedorov, V. N.; Smirnov, N. A.; Shetnev, A. A.; Leonova, O. V. |
| 2024 | The evaluation of pharmacokinetic parameters of 4-(5-methyl-1,3,4-oxadiazole-2-yl)- benzenesulfonamide and its metabolites in rat plasma | Khokhlov, A. L.; Yaichkov, I. I.; Shetnev, A. A.; Korsakov, M. K.; Volkhin, N. N. |
